Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer

World Journal of Surgical Oncology

Volumn 9, Issue , 2011, Pages

  Consorti, Fabrizio ^a   Di Tanna, Gianluca ^b   Milazzo, Francesca ^a   Antonaci, Alfredo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Breast cancer; Risk factor; Second primary malignancy; Thyroid cancer

Indexed keywords

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER SCREENING; FEMALE; FOLLOW UP; HUMAN; INTERVIEW; LIFESTYLE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; NULLIPARA; PHYSICAL ACTIVITY; PRIMARY TUMOR; RISK FACTOR; SMOKING; STANDARDIZED INCIDENCE RATIO; THYROID CANCER; ADJUVANT THERAPY; BIOPSY; BREAST TUMOR; COMPARATIVE STUDY; INCIDENCE; ITALY; MIDDLE AGED; PAPILLARY CARCINOMA; PARITY; PREGNANCY; PROGNOSIS; QUESTIONNAIRE; RETROSPECTIVE STUDY; SECOND CANCER; THYROID TUMOR; THYROIDECTOMY; TIME;

BIOPSY; BREAST NEOPLASMS; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; ITALY; LIFE STYLE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PARITY; PREGNANCY; PROGNOSIS; QUESTIONNAIRES; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS;

EID: 80051589648     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-9-88     Document Type: Article

References (16)

1. GLOBOCAN 2008 Cancer Incidence and Mortality Worldwide in 2008. , http://globocan.iarc.fr/
2. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, Straus S, Brierley JD, Tsang RW, Gafni A, Rotstein L, Sawka AM. Second Primary Malignancy Risk in Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis. THYROID 2007, 17:1277-1289. 10.1089/thy.2007.0171, 18020916.
3. Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R. The Development of Breast Carcinoma in Women with Thyroid Carcinoma. CANCER 2001, 92:225-231. 10.1002/1097-0142(20010715)92:2<225::AID-CNCR1313>3.0.CO;2-B, 11466673.
4. Adjadj E, Rubino C, Shamsaldim A, G Lê M, Schlumberger M, de Vathaire F. The Risk of Multiple Primary Breast and Thyroid Carcinomas. CANCER 2003, 6:1309-1317.
5. Canchola AJ, Horn-Ross PL, Purdie DM. Risk of Second Primary Malignancies in Women with Papillary Thyroid Cancer. Am J Epidemiol 2006, 163:521-527. 10.1093/aje/kwj072, 16421240.
6. Morris JA, Gardner MJ. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed) 1988, 296(6632):1313-1316.
7. Piscitelli P, Santoriello A, Buonaguro FM, Di Maio M, Iolascon G, Gimigliano F, Marinelli A, Distante A, Serravezza G, Sordi E, Cagossi K, Artioli F, Santangelo M, Fucito A, Gimigliano R, Brandi ML, Crespi M, Giordano A. Incidence Of Breast Cancer In Italy: Mastectomies And Quadrantectomies Performed Between 2000 and 2005. J Exp & Clin Cancer Res 2009, 28:86. 10.1186/1756-9966-28-86, 21834126.
8. Dal Maso L, Lise M, Zambon P, Falcini F, Crocetti E, Serraino D, Cirilli C, Zanetti R, Vercelli M, Ferretti S, Stracci F, De Lisi V, Busco S, Tagliabue G, Budroni M, Tumino R, . Giacomin A & Franceschi S for AIRTUM Working Group Incidence Of Thyroid Cancer In Italy, 1991-2005: Time Trends And Age-Period-Cohort Effects. Ann Oncol 2010, Giacomin A & Franceschi S for AIRTUM Working Group.
9. La Vecchia C, Bosetti C, Bertuccio P, Negri E, Boyle P, Levi F. Cancer Mortality In Europe, 2000-2004, And An Overview Of Trends Since 1975. Ann Oncol 2010, 21(6):1323-1360. 10.1093/annonc/mdp530, 19948741.
10. AIRT Rapporto tumori 2006, e&p. 2006, 2:80-81. accessed on 09/12/2010., http://www.registri-tumori.it/incidenza1998-2002/rapporto/Schede%20specifiche%20per%20tumore/Tumore%20della%20tiroide.pdf
11. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer. J Clin Endocrinol Metab 2008, 93(2):504-515. 10.1210/jc.2007-1154, 18029468.
12. Lester SC, Cotran RS. Mammary Gland. Robbins Pathologic Basis Of Disease 1999, 1282-1284. Philadelphia: Saunders, Cotran, Kumar, Collins, 6.
13. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M. Second Primary Malignancies In Thyroid Cancer Patients. Br J of Cancer 2003, 89:1638-1644.
14. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP. Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis. THYROID 2009, 19:451-456. 10.1089/thy.2008.0392, 19281429.
15. Paes JE, Hua K, Nagy R, Kloos RT, Jarjoura D, and Ringel MD. The Relationship Between Body Mass Index And Thyroid Cancer Pathology Features And Outcomes: A Clinicopathological Cohort Study. J Clin Endocrinol Metab 2010, 95(9):4244-4250. 10.1210/jc.2010-0440, 2936072, 20519347.
16. Hall LC, Salazar EP, Kanea SR, Liu N. Effects Of Thyroid Hormones On Human Breast Cancer Cell Proliferation. J Steroid Biochem & Molec Biol 2008, 109:57-66. 10.1016/j.jsbmb.2007.12.008, 2214787.